Effect of Glucuronosyltransferase (UGT) Genetic Variation on Pharmacokinetics of Empagliflozin
- Sponsor
- Ain Shams University
- Study ID
- NCT05036421
- Phase
- PHASE3
- Status
- Completed
Conditions
- Pharmacogenomic
- Pharmacokinetics
Eligibility Criteria
- Sex
- MALE
- Age
- 18 Years - 45 Years
- Healthy Volunteers
- Accepted
Interventions
- Empagliflozin 10 milligram — DRUGantihyperglycemic medication
Study Details
The aim of this works is to investigate the effect of genetic polymorphism of snps on human response to treatment with empagliflozin and its correlation with with pharmacokinetic parameters in Egyptian subjects
Key Dates
- Start date
- Feb 15, 2022
- Status verified
- Feb 2023
- Primary completion
- May 20, 2022
- Completion
- May 20, 2022
Study Design
- Enrollment
- 18 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- OTHER
Arms
- Experimental: Study GroupEmpagliflozin
Primary Outcome Measure
Pharmacokinetic parameters [ Time Frame: 48 hours ]
Related Studies
- MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic FunctionPHASE1 · Not Yet Recruiting · Resilient Pharmaceuticals · Knoxville, Tennessee
- Liposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After ThoracoscopyPHASE4 · Recruiting · Milton S. Hershey Medical Center · Hershey, Pennsylvania
- Phase1/2a Study for IPG7236 in Patients With Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Nanjing Immunophage Biotech Co., Ltd · Portland, Oregon
- Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)PHASE1 · Recruiting · Ensysce Biosciences · Miami, Florida